692 related articles for article (PubMed ID: 19534531)
1. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Zachariae U; Giordanetto F; Leach AG
J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
[TBL] [Abstract][Full Text] [Related]
2. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
3. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels.
Perrin MJ; Kuchel PW; Campbell TJ; Vandenberg JI
Mol Pharmacol; 2008 Nov; 74(5):1443-52. PubMed ID: 18701618
[TBL] [Abstract][Full Text] [Related]
4. A novel structure-based virtual screening model for the hERG channel blockers.
Du L; Li M; You Q; Xia L
Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
[TBL] [Abstract][Full Text] [Related]
5. Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition.
Yi H; Cao Z; Yin S; Dai C; Wu Y; Li W
J Proteome Res; 2007 Feb; 6(2):611-20. PubMed ID: 17269718
[TBL] [Abstract][Full Text] [Related]
6. Refining insights into high-affinity drug binding to the human ether-à-go-go-related gene potassium channel.
Hancox JC; James AF
Mol Pharmacol; 2008 Jun; 73(6):1592-5. PubMed ID: 18381562
[TBL] [Abstract][Full Text] [Related]
7. Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases.
Doddareddy MR; Klaasse EC; Shagufta ; Ijzerman AP; Bender A
ChemMedChem; 2010 May; 5(5):716-29. PubMed ID: 20349498
[TBL] [Abstract][Full Text] [Related]
8. Topological mapping of the asymmetric drug binding to the human ether-à-go-go-related gene product (HERG) potassium channel by use of tandem dimers.
Myokai T; Ryu S; Shimizu H; Oiki S
Mol Pharmacol; 2008 Jun; 73(6):1643-51. PubMed ID: 18326583
[TBL] [Abstract][Full Text] [Related]
9. A composite model for HERG blockade.
Kramer C; Beck B; Kriegl JM; Clark T
ChemMedChem; 2008 Feb; 3(2):254-65. PubMed ID: 18061919
[TBL] [Abstract][Full Text] [Related]
10. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
[TBL] [Abstract][Full Text] [Related]
11. A binary QSAR model for classification of hERG potassium channel blockers.
Thai KM; Ecker GF
Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
[TBL] [Abstract][Full Text] [Related]
12. Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques.
Ekins S; Balakin KV; Savchuk N; Ivanenkov Y
J Med Chem; 2006 Aug; 49(17):5059-71. PubMed ID: 16913696
[TBL] [Abstract][Full Text] [Related]
13. [HERG K+ channel, the target of anti-arrhythmias drugs].
Guan FY; Yang SJ
Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
[TBL] [Abstract][Full Text] [Related]
14. Computer simulations of structure-activity relationships for HERG channel blockers.
Boukharta L; Keränen H; Stary-Weinzinger A; Wallin G; de Groot BL; Aqvist J
Biochemistry; 2011 Jul; 50(27):6146-56. PubMed ID: 21657256
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets.
Shen MY; Su BH; Esposito EX; Hopfinger AJ; Tseng YJ
Chem Res Toxicol; 2011 Jun; 24(6):934-49. PubMed ID: 21504223
[TBL] [Abstract][Full Text] [Related]
16. Determination of hERG channel blockers using a decision tree.
Gepp MM; Hutter MC
Bioorg Med Chem; 2006 Aug; 14(15):5325-32. PubMed ID: 16616507
[TBL] [Abstract][Full Text] [Related]
17. Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.
Karczewski J; Wang J; Kane SA; Kiss L; Koblan KS; Culberson JC; Spencer RH
Biochem Pharmacol; 2009 May; 77(10):1602-11. PubMed ID: 19426697
[TBL] [Abstract][Full Text] [Related]
18. Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamics and drug docking studies.
Masetti M; Cavalli A; Recanatini M
J Comput Chem; 2008 Apr; 29(5):795-808. PubMed ID: 17926340
[TBL] [Abstract][Full Text] [Related]
19. Medicinal chemistry of hERG optimizations: Highlights and hang-ups.
Jamieson C; Moir EM; Rankovic Z; Wishart G
J Med Chem; 2006 Aug; 49(17):5029-46. PubMed ID: 16913693
[No Abstract] [Full Text] [Related]
20. An automated docking protocol for hERG channel blockers.
Di Martino GP; Masetti M; Ceccarini L; Cavalli A; Recanatini M
J Chem Inf Model; 2013 Jan; 53(1):159-75. PubMed ID: 23259741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]